Skip to main content
SpringerLink
Log in

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0–2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval; 7–16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47:5–27, 1997

    Google Scholar 

  2. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, WEiss GR, Magalik A, Macdonald JS: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13(6):1303–1311, 1995

    Google Scholar 

  3. Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54:1431, 1994

    Google Scholar 

  4. Ogawa M: New systemic drugs in the treatment of gastrointestinal cancer. Curr Opin Oncol 8:317–320, 1996

    Google Scholar 

  5. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufman SH, Donehower RC: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10(4):647–656, 1992

    Google Scholar 

  6. Burris H, Fields S: Clinical update on the topoisomerase I inhibitors. American Society of Clinical Oncology Education Books, 31st Annual Meeting (May 20–23, 1995), pp 104–111

Download references

Author information

Authors and Affiliations

  1. Temple University, Philadelphia, Pennsylvania, USA

    John S. Macdonald

  2. Southwest Oncology Group Statistical Center, Seattle, Washington, USA

    Jacqueline K. Benedetti

  3. Greater Phoenix CCOP, Phoenix, Arizona, USA

    Manuel Modiano

  4. University of Arizona Cancer Center, Tucson, Arizona, USA

    David S. Alberts

Authors
  1. John S. Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline K. Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuel Modiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David S. Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macdonald, J.S., Benedetti, J.K., Modiano, M. et al. Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). Invest New Drugs 15, 357–359 (1997). https://doi.org/10.1023/A:1005941603420

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005941603420

Search

Navigation